Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

BACKGROUND: Antiangiogenic agents that specifically target vascular endothelial growth factor receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for metastatic clear cell renal cell carcinoma (ccRCC) patients. However, most patients eventually show no responses to the ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yuang, Chen, Xinglin, Ren, Xiaohan, Wang, Bao, Zhang, Qian, Bu, Hengtao, Qian, Jian, Shao, Pengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299280/
https://www.ncbi.nlm.nih.gov/pubmed/34306023
http://dx.doi.org/10.3389/fgene.2021.680369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299280/
https://www.ncbi.nlm.nih.gov/pubmed/34306023
http://dx.doi.org/10.3389/fgene.2021.680369

Ejemplares similares